Gleevec

Some articles on gleevec:

Somatic Evolution In Cancer - Somatic Evolution in Therapeutic Resistance - Resistance To BCR-ABL Targeting Drugs
... In the case of Gleevec (Imatinib), which targets the BCR-ABL fusion gene in chronic myeloid leukemia, resistance often develops through a mutation that changes the ... Gleevec is not as selective as was originally thought ... c-KIT that make the cancer cells resistant to Gleevec ...
Philadelphia Chromosome - Therapy - Tyrosine Kinase Inhibitors
... In the late 1990s, STI-571 (imatinib, Gleevec/Glivec) was identified by the pharmaceutical company Novartis (then known as Ciba Geigy) in high-throughput screens for tyrosine kinase inhibitors ... It was marketed in 2001 by Novartis as imatinib mesylate (Gleevec in the US, Glivec in Europe) ... and/or are active against the emerging Gleevec/Glivec resistant BCR-abl clones in treated patients ...